Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 6/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384814 | 0.86 | ADRA1A (0.50) | ADRA1AADRA1DHTR3AADRA2AADRA2B | |
| SCHEMBL11836199 | 0.77 | ADRA1A (0.42) | ADRA1AADRA1DHTR3AADRA2AADRA2B | |
| SCHEMBL21510387 | 0.76 | ADRA1A (0.37) | ADRA1AADRA1D | |
| Hydrochloric Acid SCHEMBL1844678 | 0.74 | ADRA1A (0.41) | ADRA1AADRA1DHTR3AADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL7094413 | 0.71 | ADRA1A (0.41) | ADRA1AADRA1DOPRK1 | |
| SCHEMBL7220457 | 0.71 | ADRA1A (0.40) | ADRA1AADRA1DHTR3AADRA2AADRA2B | |
| SCHEMBL19661014 | 0.71 | ADRA1A (0.47) | ADRA1AADRA1DHTR3AADRA2AADRA2B | |
| SCHEMBL6851433 | 0.70 | HTR3A (0.38) | ADRA1AADRA1DHTR3AADRA2AADRA2B | |
| SCHEMBL18687430 | 0.70 | HCAR2 (0.31) | — | |
| SCHEMBL17326271 | 0.69 | ADRA2A (0.37) | ADRA1AADRA1DADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180208602-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-20100256210-A1 | METHODS AND COMPOSITIONS FOR DELIVERING 5-HT3 ANTAGONISTS ACROSS THE ORAL MUCOSA | TRANSORAL PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20080213363-A1 | Ionized form capable of being converted into an un-ionized form; and buffer system changes the pH of saliva from an arbitrary initial pH to a predetermined final pH; sodium carbonate and sodium bicarbonate; acetic acid and sodium acetate; lozenge, chewing gum, dissolving tablet | TRANSORAL PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080213363-A1 | Ionized form capable of being converted into an un-ionized form; and buffer system changes the pH of saliva from an arbitrary initial pH to a predetermined final pH; sodium carbonate and sodium bicarbonate; acetic acid and sodium acetate; lozenge, chewing gum, dissolving tablet | TRANSORAL PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208602-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | ATXN2, ATXN10, ATXN2L | ADRA1A 2401/4885ADRA1D 1833/4885HTR3A 1409/4885 |
| US-20080213363-A1 | Ionized form capable of being converted into an un-ionized form; and buffer system changes the pH of saliva from an arbitrary initial pH to a predetermined final pH; sodium carbonate and sodium bicarbonate; acetic acid and sodium acetate; lozenge, chewing gum, dissolving tablet | SI, HTR3A, GALR3 | ADRA1A 1422/4885ADRA1D 1413/4885HTR3A 2/4885 |
| US-20100256210-A1 | METHODS AND COMPOSITIONS FOR DELIVERING 5-HT3 ANTAGONISTS ACROSS THE ORAL MUCOSA | SLC9A3, HTR3A, HTR3C | ADRA1A 1800/4885ADRA1D 1364/4885HTR3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.